ARTICLES BY THIS AUTHOR
- 9/30/2008
Practice Issues: Adverse Reactions
Studies look at cardiovascular effects of glitazones and adverse drug events in the elderly. - 9/29/2008
Ontarians trust pharmacists most for drug info
Ontarians view their pharmacists as the most trustworthy sources of information about prescription drugs, according to a new survey by Ipsos Reid. - 9/29/2008
Food and Drugs Act needs fix, says NDMAC
NDMAC wants Canadians to use the federal election as an opportunity to stress the need for amendments to the Food and Drugs Act. - 9/29/2008
2008 Canadian diabetes guidelines now available
The Canadian Diabetes Association has released the 2008 edition of the clinical practice guidelines for the prevention and management of diabetes in Canada. - 9/25/2008
Managing statin-induced myalgia
Muscle symptoms are the most prevalent and important adverse effects associated with stain therapy, and often result in suboptimal adherence. - 9/25/2008
Funding gap threatens future of pharmacies
Nadine Saby, president and CEO of CACDS, issues a wake up call about the future of pharmacy in Canada. - 9/25/2008
Catena for Friedreich's ataxia
Santhera Pharmaceuticals is introducing Catena for the symptomatic management of patients with Friedreich's ataxia, which is a rare, progressive neuromuscular disease. - 9/23/2008
Tasigna for chronic myeloid leukemia
In October, Novartis expects to launch Tasigna for the treatment of chronic myeloid leukemia in adults who have developed resistance or intolerance to at least one prior therapy, including imatinib. - 9/18/2008
Xarelto: new oral anticoagulant
Bayer's Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheim's Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July. - 9/17/2008
Managing milk protein allergy in infants
Cow's milk protein allergy is the most common form of milk protein allergy, occurring in 2-5% of formula-fed babies and 0.4-0.5% of breastfed babies.